About us
“When my father, Dr. Gabriele Braglia, founded AMPL in 1976, he had a simple pharmaceutical licensing business in mind. Now, over 40 years later, we’ve grown to around 680 committed employees, and together with our long-standing commercial and marketing partners, that are helping us create a large portfolio of highly innovative oncology assets. As we move forward, we will never forget our fundamental objective: to build better todays for every person affected by cancer.”
Dr. Riccardo Braglia, AMPL Group Executive Chairman
Board & Management
Our Locations
AMPL is headquartered in Lugano, Switzerland. The company has a global presence with a 360° approach of quality, state-of-the-art R&D and world-class production facility in Dublin, Ireland and subsidiaries in the United States, AMPL Therapeutics (U.S.), Inc., and AMPL Pharmaceuticals (Beijing) Co. Ltd., China.
Our Mission, Vision, and Values
We are committed to making everything we do count towards the best therapies for cancer patients—from the products we license to the rigorous standards we apply as a pharmaceutical manufacturer. At AMPL we are committed to extending the reach of our quality care and use our expertise to fulfil more unmet needs and build better todays for more patients worldwide.
Our Mission
To bring better todays to even more people through a portfolio of quality innovative oncology assets, guided by solid values of respect, integrity and quality.
Our Vision
To transform AMPL into a leading oncology company driven by our focus on extending and improving the lives of people with cancer all over the world.
Our Values
Milestones
For over 40 years, AMPL has followed its core values of quality, integrity and respect, to grow into an international business committed to improving the everyday lives of people with cancer, all over the world.
AMPL obtains exclusive rights to promote and sells Akynzeo® in the US, previously co-detailed with Eisai
AMPL signs an agreement with MEI Pharma, Inc. an oncology company focused on the clinical development of novel therapies for cancer, to enter into an exclusive licensing, development and commercialization contract for pracinostat, a Phase III-ready drug candidate for the treatment of acute myeloid leukaemia (AML) and other potential indications
Opening of AMPL International Services (AIS) and launch of AMPL Investment Fund (AIF) which is focused on early-stage investments in areas of high unmet patient need
Working for AMPL
If you are interested in a career at AMPL, or would like to take part in an internship, please visit our Working for AMPL page.